Recent studies have indicated that the CCR5 chemokine receptor may be a potential target for treating prostate cancer.
Thus, development of CCR5 antagonists may provide novel prostate cancer therapy. Anibamine, a novel pyridine quaternary alkaloid isolated from Aniba sp., was found to effectively compete with 125I-gp120 in binding to the chemokine receptor CCR5, with an IC50 = 1 μM. Anibamine is the first natural product reported as a CCR5 antagonist, and thus provides a novel structural skeleton unique from other lead compounds that have generally been identified from high-throughput screening efforts. In order to refine the lead compound's structure and improve the therapeutic index of anibamine derivatives as potential anti prostate cancer agents, the approach of "deconstruction-reconstruction-elaboration" was applied in the structure-activity relationship studies of this work. Here, we report the design, syntheses and anti prostate cancer activities of anibamine and 17 analogues. The results from the in vitro and in vivo studies described here show that this class of compounds has potential to provide novel leads as anti prostate cancer agents.
Written by:
Zhang F, Arnatt CK, Haney KM, Fang HC, Bajacan JE, Richardson AC, Ware JL, Zhang Y. Are you the author?
Department of Medicinal Chemistry, Virginia Commonwealth University, 800 E Leigh Street, Richmond, VA 23298-0540, USA.
Reference: Eur J Med Chem. 2012 Sep;55:395-408.
doi: 10.1016/j.ejmech.2012.07.049
PubMed Abstract
PMID: 22901310
UroToday.com Investigative Urology Section
